MetaQon: Making Precision Health More Personalised and Preventive
November 03, 2026 | Tuesday | Features
MetaQon Precision Health Inc. is building a precision-health platform that combines genomics, diagnostic biomarkers and lifestyle intelligence to develop personalised preventive health strategies. With a focus on populations historically underrepresented in genetic research, the company aims to make genomic insights more relevant, actionable and accessible across India, the Middle East and other emerging markets.
Problem
Much of modern genetic research and risk interpretation has historically relied on data from European-ancestry populations, potentially limiting its relevance to other ethnic groups. In addition, genetic reports often provide risk information without connecting it to current biomarkers, lifestyle factors or actionable clinical decisions. MetaQon aims to bridge this gap through a more integrated approach to preventive healthcare.
Product
MetaQon combines three layers of health intelligence: genetic testing, diagnostic biomarkers and lifestyle assessment. Its platform offers more than 70 precision panels, covering 89 million-plus genetic markers and over 100 blood biomarkers. Powered by its intelligence partner Precisya, the platform connects genetic findings with scientific literature and clinician-led interpretation to develop personalised prevention strategies.
Proof
MetaQon has developed partnerships with Precisya for precision-health intelligence and Cellestra Clinique for clinical consulting. On 17 September 2026, the company announced the India rollout of MetaQon Reproductive Intelligence, a pre-cycle fertility assessment combining whole-genome analysis, targeted blood biomarkers and symptom evaluation to support IVF clinics in identifying potential reproductive risks.
People
MetaQon is co-founded by Yashpal Jain, CEO, and Shabbir Hussain Zahab, COO. The leadership team combines experience in digital transformation, product development and business operations, supported by clinical expertise from Dr Pavithrah Marimuthu, Executive Director of its consulting partner Cellestra Clinique.
Purse
MetaQon's official website and published company announcements do not currently disclose a confirmed institutional funding round or total capital raised. The company has been developing its clinical partnerships, technology infrastructure and regional distribution network as it builds its commercial operations.
Plan
MetaQon plans to expand its precision-health distribution network across India, the GCC and Southeast Asia. Its priorities include onboarding hospitals and fertility clinics, expanding its reproductive, cardiovascular and metabolic health offerings, and developing AI-enabled counselling and personalised health intelligence capabilities.
Why it matters:
MetaQon is addressing a critical gap in preventive healthcare: translating genetic information into meaningful clinical decisions. By combining genomics, biomarkers and lifestyle data, the company is working towards a more personalised model of healthcare, with particular relevance for populations inadequately represented in conventional genetic datasets.
FAST FACTS
|
Category
|
Details
|
|
Company
|
MetaQon Precision Health Inc.
|
|
Incorporation
|
Delaware, USA
|
|
Regional presence
|
India, UAE and wider GCC markets
|
|
Founders
|
Yashpal Jain and Shabbir Hussain Zahab
|
|
Industry
|
HealthTech, Precision Medicine, Genomics
|
|
Core offering
|
Personalised preventive health and genomic intelligence
|
|
Technology partner
|
Precisya
|
|
Clinical consulting partner
|
Cellestra Clinique
|
|
Precision panels
|
70+
|
|
Genetic markers
|
89 million+
|
|
Blood biomarkers
|
100+
|
|
Latest product launch
|
Reproductive Intelligence, India rollout announced 17 September 2026
|
|
Funding
|
No confirmed institutional funding publicly disclosed
|
|
Next
|
Expand clinical partnerships, regional distribution and AI-powered precision-health services
|
Disclaimer: This profile is based on publicly available company information and official announcements reviewed as of 3 November 2026. \
